AGED Diagnostics Epigenetic Modifications of Liver Disease Assessment
Continue development of previously established methods to further validate candidate biomarkers that can discriminate steatosis from NASH and separately stage fibrosis from blood. The first assessment is to conduct test method verification to expand sample size to several hundred samples through whole genome sequencing methods. The second assessment is focused on biomarker validation by comparing targeted sequencing from patient plasma. Several sub- assessments will be conducted to support overall biomarker development efforts.
100 项与 ACTIVE GENOMES EXPRESSED DIAGNOSTICS CORP 相关的临床结果
0 项与 ACTIVE GENOMES EXPRESSED DIAGNOSTICS CORP 相关的专利(医药)
100 项与 ACTIVE GENOMES EXPRESSED DIAGNOSTICS CORP 相关的药物交易
100 项与 ACTIVE GENOMES EXPRESSED DIAGNOSTICS CORP 相关的转化医学